Insider · CIK 0001646395
Maykin Ho
director
Files at KYNB (FIBROGEN INC), BMRN (BIOMARIN PHARMACEUTICAL INC), AGIO (AGIOS PHARMACEUTICALS, INC.), NMRA (Neumora Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | MOption exercise Common stock | +2,120 | $0.00 | $0 | 17,032 | Jun 23, 2025 |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | AGrant or award Restricted stock unitsderivative | +2,816 | $0.00 | $0 | 2,816 | Jun 23, 2025 |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | AGrant or award Stock options (right to buy)derivative | +15,768 | $0.00 | $0 | 15,768 | Jun 23, 2025 |
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | MOption exercise Restricted stock unitsderivative | -2,120 | $0.00 | $0 | 0 | Jun 23, 2025 |
| Jun 4, 2025 | KYNB FIBROGEN INC | AGrant or award Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Jun 6, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -95,586 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,802 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,571 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +95,586 | - | - | 95,586 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +27,802 | - | - | 27,802 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +28,571 | - | - | 28,571 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | May 30, 2025 |
| May 20, 2025 | BMRN BIOMARIN PHARMACEUTICAL INC | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 28,010 | May 22, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -95,586 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,802 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,571 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +95,586 | - | - | 95,586 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +27,802 | - | - | 27,802 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +28,571 | - | - | 28,571 | Feb 18, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.